FDA un­veils guid­ance for Covid-19 tri­als

The FDA on Wednes­day is­sued new fi­nal guid­ance to help spon­sors as­sure the safe­ty of tri­al par­tic­i­pants, main­tain com­pli­ance with good clin­i­cal prac­tice (GCP) and min­i­mize the risks to tri­al in­tegri­ty dur­ing the Covid-19 pan­dem­ic.

The guid­ance comes as the Na­tion­al In­sti­tutes of Health last week ini­ti­at­ed the first Covid-19 vac­cine Phase 1 tri­al in Seat­tle. Sanofi and Re­gen­eron Phar­ma­ceu­ti­cals al­so an­nounced on Mon­day they have start­ed a Phase 2/3 tri­al at med­ical cen­ters in New York eval­u­at­ing the IL-6 tar­get­ed Kevzara (sar­ilum­ab) in pa­tients hos­pi­tal­ized with se­vere Covid-19.

In ad­di­tion, Gilead has ini­ti­at­ed two Phase 3 stud­ies at sites across Asia to eval­u­ate the safe­ty and ef­fi­ca­cy of the an­tivi­ral remde­sivir in adults di­ag­nosed with Covid-19, as well as in Ne­bras­ka, while Eu­sa Phar­ma said Wednes­day that it ini­ti­at­ed a study at a hos­pi­tal in Berg­amo, Italy for sil­tux­imab, an­oth­er IL-6 tar­get­ed mon­o­clon­al an­ti­body, for the treat­ment of pa­tients with Covid-19 who have de­vel­oped se­ri­ous res­pi­ra­to­ry com­pli­ca­tions.

FDA Guid­ance De­tails

While rec­og­niz­ing that pro­to­col mod­i­fi­ca­tions may be re­quired, and that there may be un­avoid­able pro­to­col de­vi­a­tions due to Covid-19 ill­ness and/or Covid-19 con­trol mea­sures, FDA urges spon­sors and clin­i­cal in­ves­ti­ga­tors to en­gage with In­sti­tu­tion­al Re­view Boards (IRBs)/In­de­pen­dent Ethics Com­mit­tees (IECs) “as ear­ly as pos­si­ble when ur­gent or emer­gent changes to the pro­to­col or in­formed con­sent are an­tic­i­pat­ed as a re­sult of COVID-19.”

But FDA al­so says that such changes to the pro­to­col or in­ves­ti­ga­tion­al plan to min­i­mize or elim­i­nate im­me­di­ate haz­ards or to pro­tect the life and well-be­ing of re­search par­tic­i­pants (e.g., to lim­it ex­po­sure to Covid-19) “may be im­ple­ment­ed with­out IRB ap­proval or be­fore fil­ing an amend­ment to the IND or IDE, but are re­quired to be re­port­ed af­ter­wards.”

David Bo­rasky, VP of IRB Com­pli­ance at WCG, said in a we­bi­nar on Covid-19 tri­als on Wednes­day that IRBs want to know about changes as soon as pos­si­ble and hope that they’ll be re­port­ed with­in five days, but they un­der­stand the cir­cum­stances.

He added that IRBs should not be a road­block to mak­ing changes that are es­sen­tial to main­tain­ing re­search that is eth­i­cal­ly ap­pro­pri­ate, max­i­mizes the safe­ty of study par­tic­i­pants and re­search teams, sci­en­tif­i­cal­ly valid and com­pli­ant with the reg­u­la­tions.

As far as ef­fi­ca­cy as­sess­ments, FDA’s guid­ance “rec­om­mends con­sul­ta­tion with the ap­pro­pri­ate re­view di­vi­sion re­gard­ing pro­to­col mod­i­fi­ca­tions for the col­lec­tion of ef­fi­ca­cy end­points, such as use of vir­tu­al as­sess­ments, de­lays in as­sess­ments, and al­ter­na­tive col­lec­tion of re­search-spe­cif­ic spec­i­mens, if fea­si­ble. For in­di­vid­ual in­stances where ef­fi­ca­cy end­points are not col­lect­ed, the rea­sons for fail­ing to ob­tain the ef­fi­ca­cy as­sess­ment should be doc­u­ment­ed (e.g., iden­ti­fy­ing the spe­cif­ic lim­i­ta­tion im­posed by COVID-19 lead­ing to the in­abil­i­ty to per­form the pro­to­col-spec­i­fied as­sess­ment).”

And pri­or to lock­ing the data­base, the 9-page guid­ance says spon­sors should use its sta­tis­ti­cal analy­sis plan to ad­dress how pro­to­col de­vi­a­tions re­lat­ed to Covid-19 will be han­dled for the pre­spec­i­fied analy­ses.

In ad­di­tion, the guid­ance adds that spon­sors and clin­i­cal in­ves­ti­ga­tors should doc­u­ment how Covid-19-re­lat­ed re­stric­tions led to changes in study con­duct and the du­ra­tion of those changes, as well as in­di­cat­ing which tri­al par­tic­i­pants were im­pact­ed and how those tri­al par­tic­i­pants were im­pact­ed.

“Spon­sors, in con­sul­ta­tion with clin­i­cal in­ves­ti­ga­tors and, may de­ter­mine that the pro­tec­tion of a par­tic­i­pant’s safe­ty, wel­fare, and rights is best served by con­tin­u­ing a study par­tic­i­pant in the tri­al as per the pro­to­col or by dis­con­tin­u­ing the ad­min­is­tra­tion or use of the in­ves­ti­ga­tion­al prod­uct or even par­tic­i­pa­tion in the tri­al. Such de­ci­sions will de­pend on spe­cif­ic cir­cum­stances, in­clud­ing the na­ture of the in­ves­ti­ga­tion­al prod­uct, the abil­i­ty to con­duct ap­pro­pri­ate safe­ty mon­i­tor­ing, the po­ten­tial im­pact on the in­ves­ti­ga­tion­al prod­uct sup­ply chain, and the na­ture of the dis­ease un­der study in the tri­al,” the guid­ance adds.

Dif­fi­cul­ties in get­ting prospec­tive pa­tients to tri­al sites al­so mean that spon­sors should eval­u­ate whether al­ter­na­tive meth­ods for safe­ty as­sess­ments (e.g., phone con­tact, vir­tu­al vis­it, al­ter­na­tive lo­ca­tion for as­sess­ment, in­clud­ing lo­cal labs or imag­ing cen­ters) could be im­ple­ment­ed when nec­es­sary and fea­si­ble, and would be suf­fi­cient to as­sure the safe­ty of tri­al par­tic­i­pants, FDA says.

“COVID-19 screen­ing pro­ce­dures that may be man­dat­ed by the health care sys­tem in which a clin­i­cal tri­al is be­ing con­duct­ed do not need to be re­port­ed as an amend­ment to the pro­to­col even if done dur­ing clin­i­cal study vis­its un­less the spon­sor is in­cor­po­rat­ing the da­ta col­lect­ed as part of a new re­search ob­jec­tive,” the guid­ance adds.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Tesla and SpaceX founder Elon Musk gestures to the audience after being recognized by President Trump following the successful launch of a Falcon 9 rocket at the Kennedy Space Center. (via Getty Images)

Tes­la chief Elon Musk teams up with Covid-19 play­er Cure­Vac to build 'R­NA mi­cro­fac­to­ries'

Elon Musk has joined the global tech crusade now underway to revolutionize vaccine manufacturing — now aimed at delivering billions of doses of a new mRNA vaccine to fight Covid-19. And he’s cutting right to the front.

In a late-night tweet Wednesday, the Tesla chief announced:

Tesla, as a side project, is building RNA microfactories for CureVac & possibly others.

That’s not a lot to go on. But the tweet comes a year after Tesla’s German division in Grohmann and CureVac filed a patent on a “bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing.” CureVac, in the meantime, has discussed a variety of plans to build microfactories that can speed up the whole process for a global supply chain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (Regeneron)

UP­DAT­ED: Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

Typically, the commencement speech at Yorktown Central School District in Westchester — like most high schools — is an opportunity to encourage students to face the future with confidence and hope. Regeneron president and co-founder George Yancopoulos, though, went a different route.

In a fiery speech, the outspoken billionaire defended the police against the “prejudice and bias against law enforcement” that has erupted around the country in street protests from coast to coast. And for many who attended the commencement, Yancopoulos struck the wrong note at the wrong time, especially when he combatively challenged someone for interrupting his speech with a honk for “another act of cowardness.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Elias Zerhouni (Photo by Vincent Isore/IP3/Getty Images)

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

Elias Zerhouni favors blunt talk, and in a recent discussion with NPR, the ex-Sanofi R&D and ex-NIH chief had some tough points to make regarding the pandemic response.

Rather than interpret them, I thought it would be best to provide snippets straight from the interview.

On the Trump administration response:

It was basically amateur hour. There is no central concept of operations for preparedness, for pandemics, period. This administration doesn’t want to or has no concept of what it takes to protect the American people and the world because it is codependent. You can’t close your borders and say, “OK, we’re going to be safe.” You’re not going to be able to do that in this world. So it’s a lack of vision, basically just a lack of understanding, of what it takes to protect the American people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.

The incidents are derailing plans to file for a near-term approval, which had been expected right about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

Pfizer and their partners at the mRNA specialist BioNTech have published the first glimpse of biomarker data from an early-stage study spotlighting the “robust immunogenicity” triggered by their Covid-19 vaccine, which is one of the leaders in the race to vanquish the global pandemic.

Researchers selected 45 healthy volunteers 18-55 years of age for the study. They were randomized to receive 2 doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, “a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD.” Their responses were compared against the effect of a natural, presumably protective defense offered by a regular infection.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

New stan­dard of care? FDA hands Pfiz­er, Mer­ck KGaA an OK for Baven­cio in blad­der can­cer

The breakthrough therapy designation Pfizer and Merck KGaA notched for Bavencio in bladder cancer has quickly paved way for a full approval.

The PD-L1 drug is now sanctioned as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma, applicable in cases where cancer hasn’t progressed after platinum-containing chemotherapy.

Petros Grivas, the principal investigator of the supporting Phase III JAVELIN Bladder 100, called the approval “one of the most significant advances in the treatment paradigm in this setting in 30 years.”

Covid-19 roundup: Vac­cines will need to beat place­bo by 50% to qual­i­fy for FDA OK; UK tri­al drops Kale­tra

The FDA will set the bar for approving a Covid-19 vaccine at 50% efficacy, the Wall Street Journal reported, meaning any successful candidate will have to reduce the risk of coronavirus disease by at least half compared to placebo.

That requirement is part of guidance that the agency is set to release later today, laying out detailed criteria for vaccine developers — some of whom are eyeing an OK by the end of the year, in line with expectations at Operation Warp Speed.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

On a roll, Mer­ck blazes through a new seg­ment of the bio­mark­er trail

Merck has notched an approval for using Keytruda to treat a biomarker-based subset of first-line colorectal cancer patients with unresectable or metastatic tumors, as the pharma giant continues to find new niches for its blockbuster PD-1 star.

The OK is significant in a number of ways. Not only does it build on an accelerated approval for all tumors characterized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR); it also marks the first single treatment for colorectal cancer that doesn’t contain chemotherapy.

No­var­tis los­es biosim­i­lar ap­peal as court up­holds a 31-year mo­nop­oly by Am­gen's En­brel

A new court ruling has strengthened Amgen’s grip on the IP estate around Enbrel, keeping biosimilars of the autoimmune and inflammatory drug at bay until 2029.

Novartis, the patent challenger, isn’t throwing in the towel yet. In a statement noting the failed appeal, its generics division Sandoz noted its reviewing options, “including potential appeal to US Supreme Court.”

It’s been almost four years since the FDA approved Erelzi, Sandoz’s copycat version of Enbrel. While sales of the Pfizer-partnered drug in the US — the market Amgen is in charge of — have dipped slightly during that time, it remains a solid megablockbuster with 2019 revenue slightly above $5 billion.